The binge eating disorder market was valued at USD 0.81 Billion in 2024 driven by increasing awareness, advancements in treatment options, and the rising prevalence of the disorder across the 8 major markets. It is expected to grow at a CAGR of 6.00% during the forecast period 2025-2034 and attain a market value of USD 1.45 Billion by 2034.
Genetic factors, hormonal imbalances, and dopamine are all factors that influence the development and severity of the disorder. Mental health problems such as depression, anxiety, and previous trauma can lead to episodes of binge eating, along with emotional stressors. Societal expectations, limited eating habits, and genetic predisposition for eating disorders may elevate the chances of developing one.
Binge eating disorder treatment typically includes a mix of counseling, drugs, and adjustments in lifestyle. Cognitive behavioral therapy (CBT) is successful in handling triggers, while drugs such as lisdexamfetamine and antidepressants aid in diminishing cravings and balancing mood.
The United States is expected to dominate the market because of the high prevalence of the disorder and the availability of advanced treatment options, along with extensive awareness initiatives and strong healthcare facilities encouraging treatment acceptance. Drugs such as lisdexamfetamine and treatments like CBT are frequently utilized, supported by insurance and government efforts.
There has been a significant increase in market growth in the EU-4 countries and the United Kingdom due to the rising awareness of eating disorders as serious health issues, leading to more investment in mental health services and a higher demand for treatments. The market in Japan and India is rapidly expanding driven by greater awareness, diagnosis rates,h ealthcare infrastructure enhancements, lifestyle modifications, urbanization, and stress.
Other players in the market are Takeda Pharmaceutical Company Limited, VIVUS LLC, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics Inc., Jazz Pharmaceuticals Inc., and Novo Nordisk A/S.
This product will be delivered within 3-5 business days.
Binge Eating Disorder Market Overview
Binge eating disorder (BED) is characterized by excessive eating within a short period, without engaging in purging behaviors such as vomiting. It can result in obesity, heart disease, and emotional problems. BED is the result of a combination of genetic, psychological, and environmental factors such as genetics, lack of self-confidence, and societal influences. Binge episodes can be exacerbated by stress and negative emotions.Genetic factors, hormonal imbalances, and dopamine are all factors that influence the development and severity of the disorder. Mental health problems such as depression, anxiety, and previous trauma can lead to episodes of binge eating, along with emotional stressors. Societal expectations, limited eating habits, and genetic predisposition for eating disorders may elevate the chances of developing one.
Binge eating disorder treatment typically includes a mix of counseling, drugs, and adjustments in lifestyle. Cognitive behavioral therapy (CBT) is successful in handling triggers, while drugs such as lisdexamfetamine and antidepressants aid in diminishing cravings and balancing mood.
Binge Eating Disorder Market Growth Drivers
Increasing Prevalence of Binge Eating Disorder Spurs Market Growth
The rising occurrence of binge eating disorder is driving the growth of the market as awareness of mental health increases. As per the Eating Recovery Center’s eating disorder statistics for 2024, 28.8 million Americans, or 9% of the U.S. population, will experience an eating disorder at some point in their lives. Each year, 10,200 deaths occur due to eating disorders, resulting in one death every 52 minutes. Urbanization, inactive lifestyles, and high-stress levels lead to a rise in BED cases, particularly in developed areas.Growing Awareness and Diagnosis to Meet Rising Binge Eating Disorder Market Demand
Efforts in public health campaigns and education have contributed to raising awareness of BED as a significant mental health condition. During the National Eating Disorders Awareness Week in February 2024, Monte Nido & Affiliates conducted an educative session on binge eating disorder. As a leading eating disorder treatment provider in the United States, they offer vital resources and expanded virtual treatment programs in 28 states. Their specialty program addresses core features of shame, guilt, and self-blame associated with binge eating disorder, encouraging individuals to seek help for mental health issues without fear of judgment has led to an increase in early diagnoses. Healthcare providers have improved their skills in recognizing BED, resulting in an increased need for treatment choices.Binge Eating Disorder Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advances in Treatments
Progress in treatments is leading to a rise in the need for medication-based therapies that focus on the neurological and psychological components of BED. Continued studies on novel drugs are expanding the range of treatment options, as pharmaceutical companies are funding clinical trials to create better treatments with reduced side effects. This is helping to tailor treatment plans to individuals and maintain market growth for treatments of BED.Rising Use of Non-Invasive Therapies to Boost Binge Eating Disorder Market Value
Non-intrusive treatments like cognitive behavioral therapy (CBT) are gaining popularity for addressing BED. These treatments concentrate on altering eating habits and emotional cues without requiring invasive techniques. Treatment plans also incorporate group therapy, family counseling, and nutritional education among others.Rising Focus on Mental Health in Corporate Wellness Programs
The increasing focus on mental health in company wellness initiatives is resulting in the inclusion of resources for the condition. Businesses are broadening their benefits packages to incorporate therapy, counseling, and stress management initiatives to tackle the consequences of untreated binge eating disorders. Educational workshops on eating disorders are being integrated to increase awareness and encourage early intervention.Use of Digital Therapeutics
Digital therapeutics are influencing the treatment of BED by providing accessible resources such as mobile apps and online platforms for self-directed programs and cognitive behavioral therapy. These electronic tools enable people to monitor their symptoms in real-time and get remote assistance via telehealth services, especially helping younger patients and those in disadvantaged regions. The demand for digital therapeutics in treating BED is rising due to their cost efficiency and effectiveness.Binge Eating Disorder Market Segmentation
The report titled “Binge Eating Disorder Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:Market Breakup by Drug Class
- Antidepressant
- Anticonvulsant
- Anti-obesity Medication
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Japan
- India
Binge Eating Disorder Market Share
Market Share Based on Route of Administration to Witness Substantial Growth
Based on the route of administration, the market is divided into oral, parenteral, and others. The most frequent administration is through oral administration, where drugs such as lisdexamfetamine and antidepressants can be easily included in daily schedules. Oral medications allow for flexibility in dosage and self-administration, increasing accessibility and affordability for long-term treatment.Binge Eating Disorder Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.The United States is expected to dominate the market because of the high prevalence of the disorder and the availability of advanced treatment options, along with extensive awareness initiatives and strong healthcare facilities encouraging treatment acceptance. Drugs such as lisdexamfetamine and treatments like CBT are frequently utilized, supported by insurance and government efforts.
There has been a significant increase in market growth in the EU-4 countries and the United Kingdom due to the rising awareness of eating disorders as serious health issues, leading to more investment in mental health services and a higher demand for treatments. The market in Japan and India is rapidly expanding driven by greater awareness, diagnosis rates,h ealthcare infrastructure enhancements, lifestyle modifications, urbanization, and stress.
Leading Players in the Binge Eating Disorder Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals is a biopharmaceutical company dedicated to creating new treatments for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. In July 2023, they started enrolling participants in the MGH Phase 2 'STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the treatment of binge-eating disorder in July 2023.Chronos Therapeutics Limited
Chronos Therapeutics Ltd is a UK-based pharmaceutical company focused on developing drugs for neurodegenerative diseases. They are a major player in the binge eating disorder market, utilizing Orexin -1 Antagonist research for effective treatment with minimal side effects.Pyramid Healthcare Inc.
Pyramid Healthcare offers a range of healthcare services in the United States, including residential and outpatient treatment, dual diagnosis, mental health, transitional housing, and specialty programs for substance abuse, mental health, autism, and eating disorders.Eli Lilly and Company
Eli Lilly and Company in Indianapolis, Indiana is a healthcare company developing medications for various health conditions. The FDA approved Lilly's Zepbound (tirzepatide) in November 2023 for chronic weight management, providing a new treatment option for those struggling with obesity or being overweight with weight-related medical issues.Other players in the market are Takeda Pharmaceutical Company Limited, VIVUS LLC, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics Inc., Jazz Pharmaceuticals Inc., and Novo Nordisk A/S.
Key Questions Answered in the Binge Eating Disorder Market Report
- What was the binge eating disorder market value in 2024?
- What is the binge eating disorder market forecast outlook for 2025-2034?
- What are the regional markets covered in the report?
- What is the market segmentation based on drug class?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on distribution channels?
- What are the major factors aiding the binge eating disorder market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the binge eating disorder market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Binge Eating Disorder Market Overview: 8 Major Market
4 Vendor Positioning Analysis
5 Binge Eating Disorder: Disease Overview
6 Patient Profile
7 Binge Eating Disorder Market Epidemiology Scenario and Forecast - 8 Major Markets
8 Binge Eating Disorder Market Landscape: 8 Major Market*
9 Binge Eating Disorder Market Challenges and Unmet Needs
11 Binge Eating Disorder: Market Dynamics
12 Binge Eating Disorder Market Segmentation: 8 Major Markets
13 United States Binge Eating Disorder Market (218-2034)
14 EU-4 and United Kingdom Binge Eating Disorder Market (218-2034)
15 Japan Binge Eating Disorder Market
16 India Binge Eating Disorder Market
17 Regulatory Framework
18 Patent Analysis
19 Clinical Trial Analysis
20 Grant Analysis
21 Funding and Investment Analysis
22 Strategic Initiatives
23 Supplier Landscape
24 Binge Eating Disorder Market - Distribution Model (Additional Insight)
26 Payment Methods (Additional Insight)
Companies Mentioned
- Tonix Pharmaceuticals Holding Corp
- Chronos Therapeutics Limited
- Pyramid Healthcare Inc.
- Eli Lilly and Company
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 400 |
Published | June 2025 |
Forecast Period | 2025 - 2034 |
Estimated Market Value ( USD | $ 0.81 Billion |
Forecasted Market Value ( USD | $ 1.45 Billion |
Compound Annual Growth Rate | 6.0% |
Regions Covered | Global |
No. of Companies Mentioned | 4 |